NASDAQ · TLSA
Tiziana Life Sciences financials
$0.9537−2.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Diluted shares | 118.3M | 106.7M | 102.5M | 101.5M | 97.9M | 97.3M | 97.3M | 127.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.0M | $3.7M | $1.2M | $18.1M | $42.2M | $65.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $324.0K |
| Total assets | $11.5M | $11.3M | $12.2M | $26.5M | $48.8M | $70.7M |
| Total liabilities | $11.4M | $7.3M | $6.6M | $6.9M | $7.5M | $8.3M |
| Shareholders' equity | $52.0K | $3.9M | $5.5M | $19.6M | $41.3M | $62.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology